Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 8/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.44 |
| ▸ | CDC7 | O00311 | 2/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TLR5 | O60602 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25663144 | 0.89 | CLK1 (0.42) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663136 | 0.89 | CLK1 (0.44) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663137 | 0.86 | CLK1 (0.45) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663487 | 0.86 | CLK1 (0.45) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663138 | 0.86 | CLK1 (0.47) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663140 | 0.85 | CLK1 (0.44) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663141 | 0.83 | CLK1 (0.41) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663139 | 0.83 | CLK1 (0.42) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663127 | 0.80 | CLK1 (0.44) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL25663126 | 0.80 | CLK1 (0.45) | CLK1LIMK1CDC7DBF4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172057-A1 | HETEROCYCLIC COMPOUND CONTAINING HETEROATOM SUBSTITUTED FLUORENE AND OPTOELECTRONIC DEVICE | CHRM1, CHRM2, CHRM4 | CLK1 1567/4885LIMK1 1044/4885CDC7 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.